Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind trial of MV-CHIK dose optimization in healthy volunteers
2015-004037-26Phase 2Completed
- Sponsor
- Themis Bioscience
- Start
- May 2016
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MV-CHIK in Chikungunya (CHIKV) (3 arms), sponsored by Themis Bioscience. Primary endpoint: Immunogenicity on day 56 by PRNT50. Started May 2016; status: completed.
02
Drugs
MV-CHIK
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on 2015-004037-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004037-26.